Fiche publication
Date publication
mars 2020
Journal
Retrovirology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MARCAIS Ambroise
Tous les auteurs :
Marçais A, Cook L, Witkover A, Asnafi V, Avettand-Fenoel V, Delarue R, Cheminant M, Sibon D, Frenzel L, de Thé H, Bangham CRM, Bazarbachi A, Hermine O, Suarez F
Lien Pubmed
Résumé
Adult T-cell leukemia-lymphoma (ATL) is an aggressive mature lymphoid proliferation associated with poor prognosis. Standard of care includes chemotherapy and/or the combination of zidovudine and interferon-alpha. However, most patients experience relapse less than 6 months after diagnosis. Allogeneic stem cell transplantation is the only curative treatment, but is only feasible in a minority of cases. We previously showed in a mouse model that Arsenic trioxide (AsO) targets ATL leukemia initiating cells.
Mots clés
ATL, Arsenic trioxide
Référence
Retrovirology. 2020 03 21;17(1):5
